Horst Rose
Director/Board Member at ImVision Therapeutics, Inc.
Network origin in Horst Rose first degree
Entity | Entity type | Industry | |
---|---|---|---|
Abbott Products GmbH
1
| Extinct | 1 | |
ImVision Therapeutics, Inc.
ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany.
1
| Private Company | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Horst Rose via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Behringwerke AG
Behringwerke AG Pharmaceuticals: OtherHealth Technology Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany. | Pharmaceuticals: Other | Corporate Officer/Principal | |
University of Michigan | College/University | Masters Business Admin | |
University of Vienna | College/University | Doctorate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
Apovia AG | President | ||
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
SYNIMMUNE GmbH
SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | Miscellaneous Commercial Services | Chief Executive Officer |
Statistics
International
Germany | 7 |
United States | 2 |
Austria | 2 |
Switzerland | 2 |
Belgium | 2 |
Sectoral
Commercial Services | 4 |
Consumer Services | 4 |
Health Technology | 3 |
Operational
Chief Executive Officer | 4 |
Corporate Officer/Principal | 3 |
Director of Finance/CFO | 2 |
Doctorate Degree | 2 |
Director/Board Member | 2 |
Most connected contacts
Insiders | |
---|---|
Martin Steiner | 8 |
Bernd Eisele | 4 |
- Stock Market
- Insiders
- Horst Rose
- Company connections